Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients

about

Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche.Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.Enrichment and detection of bone disseminated tumor cells in models of low tumor burden

P2860

Q37340509-6028790C-B650-4FF6-B46D-0C2B2891D785 Q47673322-F5864268-1AA7-4165-840D-BFDE3A03A28B Q58700560-D2713A2F-3791-40CB-955A-CB257D9619B8

P2860

Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients

Item

http://www.wikidata.org/entity/Q36653686

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Estrogen Receptor Status Predi ...... ence in Breast Cancer Patients

@ast

Estrogen Receptor Status Predi ...... ence in Breast Cancer Patients

@en

type

Item

label

Estrogen Receptor Status Predi ...... ence in Breast Cancer Patients

@ast

Estrogen Receptor Status Predi ...... ence in Breast Cancer Patients

@en

prefLabel

Estrogen Receptor Status Predi ...... ence in Breast Cancer Patients

@ast

Estrogen Receptor Status Predi ...... ence in Breast Cancer Patients

@en

P1476

Estrogen Receptor Status Predi ...... ence in Breast Cancer Patients

@en

P2093

Hyun Ho Han

http://www.w3.org/2001/XMLSchema#string

Joo Hyun Lee

http://www.w3.org/2001/XMLSchema#string

Nam Hoon Cho

http://www.w3.org/2001/XMLSchema#string

Sung Hwan Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis.

Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare.

Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer

Mechanisms governing metastatic dormancy and reactivation.

Tumour dormancy in breast cancer: an update

The clinical course of bone metastases from breast cancer.

P304

e2909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000002909

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Suki Kang

Baek Gil Kim

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26937933

http://www.w3.org/2001/XMLSchema#string

P932

4779030

http://www.w3.org/2001/XMLSchema#string

Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients

about

P2860

P2860

Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932